证券代码：000623 证券简称：吉林敖东 公告编号：2024-065 吉林敖东药业集团股份有限公司 股东股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份解除质押基本情况 吉林敖东药业集团股份有限公司（以下简称"公司"）接到股东敦化市金诚 实业有限责任公司（以下简称"金诚公司"）函告，获悉金诚公司所持有公司的 部分股份办理解除质押手续，具体事项如下： 1、股东股份解除质押基本情况 | | 是否为控股股东 | 本次解除质 | 占其所 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 或第一大股东及 | 押股份数量 | 持股份 | 总股本 | 起始日 | 解除日期 | 质权人 | | | 其一致行动人 | （万股） | 比例 | 比例 | | | | | 敦化市金诚实业 有限责任公司 | 是 | 1,000 | 3.06% | 0.84% | 2024.01.16 | 2024.09.06 | 上海海通证 券资产管理 | | | | | ...

证券代码：000623 证券简称：吉林敖东 公告编号：2024-064 吉林敖东药业集团股份有限公司 （一）股东股份解除质押 1、股东股份解除质押基本情况 | 股东名称 | 是否为控股股东 或第一大股东及 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司 总股本 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 其一致行动人 | （万股） | 比例 | 比例 | | | | | 敦化市金诚实业 有限责任公司 | 是 | 370 | 1.13% | 0.31% | 2024.01.16 | 2024.09.04 | 上 海 海 通 证 券 资 产 管 理 | | | | | | | | | 有限公司 | | 敦化市金诚实业 | 是 | 870 | 2.66% | 0.73% | 2022.09.05 | 2024.09.05 | 中泰证券股 | | 有限责任公司 | | | | | | | 份有限公司 | | 合计 | - | 1,240 | 3.79% | 1.04% | - | - | - | 2、 ...

Investment Rating - The report maintains a "Buy" rating for Jilin Aodong (000623.SZ) [3][7] Core Views - The company's performance in H1 2024 met expectations, with a decline in revenue and net profit primarily due to lower gross margins, reduced investment income, and fair value losses [4][5] - The company continues to manage expenses effectively, with a decrease in sales expense ratio and a slight increase in management expense ratio [4] - Jilin Aodong's pharmaceutical business remains stable, with ongoing investment in research and development to support long-term growth [5][6] Financial Performance Summary - In H1 2024, the company reported revenue of 1.412 billion yuan, a year-on-year decrease of 10.82%, and a net profit attributable to shareholders of 537 million yuan, down 49.45% [3][4] - The gross margin for H1 2024 was 37.74%, a decline of 12.25 percentage points year-on-year, attributed to an increase in low-margin business [4] - The company’s investment income from Guangfa Securities was 785 million yuan, a decrease of 6.96% year-on-year, with significant fair value losses from other investments [6] Business Segment Performance - Traditional Chinese medicine sales reached 873 million yuan, down 7.95%, accounting for 61.82% of total revenue [5] - Chemical medicine revenue was 153 million yuan, down 27.86%, representing 10.81% of total revenue, with core product sales recovering [5] - The health business generated 109 million yuan, contributing 7.73% to total revenue, with 39 products achieving over 1 million yuan in sales [5] Dividend and Shareholder Returns - The company announced a mid-year dividend of 2.00 yuan per 10 shares (before tax), totaling 239 million yuan, which is 44.50% of H1 2024 net profit, ensuring stable returns for shareholders [6] Earnings Forecast - Projected revenues for 2024-2026 are 3.667 billion yuan, 4.148 billion yuan, and 4.706 billion yuan, with net profits of 1.302 billion yuan, 2.079 billion yuan, and 2.167 billion yuan respectively [7]

Financial Performance - The company's operating revenue for the reporting period was CNY 1,411,738,702.60, a decrease of 10.82% compared to the same period last year [12]. - Net profit attributable to shareholders was CNY 537,461,062.60, down 49.45% year-on-year [12]. - The net profit after deducting non-recurring gains and losses was CNY 812,230,236.83, a decrease of 13.81% compared to the previous year [12]. - Basic earnings per share were CNY 0.4632, down 50.90% year-on-year [12]. - The company reported a revenue of CNY 141.17 million for the reporting period, a decrease of 10.82% year-on-year, and a net profit of CNY 53.75 million, down 49.45% compared to the previous year [27]. - The pharmaceutical segment generated CNY 121.43 million in revenue, accounting for 86.01% of total revenue, reflecting a decline of 10.55% year-on-year [27]. - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the first half of 2024 [48]. - The company projects a revenue growth guidance of 10% for the second half of 2024 [48]. Cash Flow and Investments - The net cash flow from operating activities improved significantly, reaching CNY -20,369,221.04, an increase of 92.87% from the previous year [12]. - Financing activities generated a net cash inflow of CNY 443,813,544.16, a significant increase of 395.08% year-on-year [56]. - The company’s cash and cash equivalents increased by CNY 307,658,479.30, although this was a decrease of 38.53% compared to the previous year [56]. - The company reported a total non-operating loss of ¥274,769,174.23, primarily due to fair value changes in financial assets and liabilities, which accounted for a loss of ¥405,794,235.42 [14]. - The company received government subsidies amounting to ¥32,494,167.15 during the reporting period [14]. - The company reported a significant loss in fair value changes amounting to CNY -408,227.33 million, contrasting with a gain of CNY 54,973.76 million in the previous year [149]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 33,424,066,025.69, an increase of 3.59% from the end of the previous year [12]. - The company's total assets reached ¥28,623,760,598.69 at the end of the reporting period [158]. - The company's total liabilities amounted to CNY 3,129,737,705.98, a slight decrease from CNY 3,168,915,774.14 in the previous period, indicating a reduction of approximately 1.23% [146]. - The total liabilities to assets ratio slightly decreased to 14.36% from 14.77% at the end of the previous year [139]. - The company's inventory increased to ¥972,309,071.74, up from ¥872,348,996.28 at the end of the previous year [143]. Research and Development - The company is committed to R&D, combining traditional Chinese medicine with modern technology to develop new products and improve existing ones, enhancing market competitiveness [25]. - The company has 18 ongoing research projects in the health product sector, progressing steadily according to project timelines [37]. - The company is focusing on the development of innovative drugs for various diseases, including cancer and neurological disorders, enhancing its product portfolio [49]. - The company has initiated 1 new drug research project and 4 generic drug research projects, along with 5 new drug development projects and 7 consistency evaluation studies [49]. - The company is actively exploring and optimizing classic TCM formulas and medicinal resources, contributing to sustainable development [49]. Market Strategy and Operations - The company operates in the pharmaceutical manufacturing industry, which is characterized by high investment, high risk, and long development cycles, with a focus on innovation and compliance with strict technical standards [16]. - The company is focused on expanding its market presence and enhancing its product offerings in response to evolving healthcare needs and regulatory changes [16]. - The sales strategy includes a professional marketing system and a nationwide sales network, integrating online and offline channels to boost sales growth [24]. - The company aims to maintain a high-quality production standard while promoting green development and ecological protection [23]. - The company has established a marketing center to enhance product structure and implement targeted marketing strategies, contributing to steady sales growth [32]. Shareholder and Dividend Information - The company plans to distribute a cash dividend of CNY 2.00 per 10 shares (including tax) to all shareholders [3]. - The company aims to enhance dividend levels and frequency to improve investor returns and confidence in future growth [91]. - The total number of shares outstanding as of June 30, 2024, is 1,195,895,387 [91]. - The company reported a net profit of 695,893,302.57 CNY for the first half of 2024, with a total distributable profit of 18,565,333,092.38 CNY [91]. Environmental and Social Responsibility - The company is committed to environmental protection, investing in upgrades to meet stricter standards and reduce pollution risks [84]. - The company has actively engaged in poverty alleviation efforts, focusing on projects such as medicinal black bean and ecological ganoderma cultivation to help local villagers increase their income [107]. - The company’s environmental facilities are operating normally, with wastewater, waste gas, and hazardous waste emissions meeting environmental requirements, indicating no major environmental issues during the reporting period [98]. - The company has implemented online monitoring for COD, ammonia nitrogen, total phosphorus, and total nitrogen, ensuring compliance with environmental standards [101]. Risk Management - The company has detailed potential risks and corresponding measures in the report, emphasizing the importance of investor awareness of investment risks [3]. - The company faces significant industry policy risks due to ongoing healthcare reforms, which may increase competition and impact profitability [81]. - The company is actively managing drug price reduction risks by expanding sales channels and enhancing production efficiency to offset potential profit declines [82]. - The company emphasizes drug quality control to mitigate risks associated with adverse drug reactions and potential legal issues [85].

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码:000623 证券简称:吉林敖东 公告编号:2024-059 吉林敖东药业集团股份有限公司 第十一届监事会第十次会议决议公告 3、本次会议应到会监事5人，实际到会监事5人。 4、会议由公司监事长陈永丰先生主持。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、监事会会议审议情况 一、监事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届监事会 第十次会议通知以书面方式于2024年8月19日发出。 2、会议于2024年8月30日在公司五楼会议室以现场方式召开。 1、审议《关于公司2024年半年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审议《2024年半年度报告全文及摘要》的 程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反 映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 2、审议《公司2024年中期现金分红预案》(本议案需提交股东大会审议） 经审核，监事会认为：公司2024年度中 ...

证券代码:000623 证券简称:吉林敖东 公告编号:2024-058 吉林敖东药业集团股份有限公司 第十一届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第十一次会议通知以书面方式于2024年8月19日发出。 2、会议于2024年8月30日在公司六楼会议室以现场结合通讯方式召开。 3、本次会议应到会董事9名，实际参加会议表决董事9名，其中李鹏先生、 肖维维女士、梁毕明先生以通讯表决方式出席本次会议。 4、会议由公司董事长李秀林先生主持，公司监事、高级管理人员列席本次 董事会会议。 5、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 二、董事会会议审议情况 1、审议《关于公司2024年半年度报告全文及摘要的议案》 董事会经审议认为：公司《2024 年半年度报告全文及摘要》的编制程序、内 容以及格式符合相关法律、法规和中国证监会规范性文件的规定和要求；公司的 财务报告真实、准确、完整地反映了报告期内公司的财 ...

民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为吉林 敖东药业集团股份有限公司（以下简称"吉林敖东"或"公司"）公开发行可转 换公司债券的保荐机构，根据《 证券发行上市保荐业务管理办法》、《 上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求《（2022 年修订）》、《 深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关 法规规章的要求，对吉林敖东使用部分闲置募集资金暂时补充流动资金之事项进 行了审慎核查，核查情况及具体核查意见如下： 一、募集资金基本情况 民生证券股份有限公司 关于吉林敖东药业集团股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 3、募集资金投资项目变更及实际使用情况 2020 年 5 月 18 日，公司召开 2019 年度股东大会、2020 年第一次债券持有 人会议，审议通过了《 关于变更部分募集资金投资项目并将剩余募集资金及其利 息永久补充流动资金的议案》，同意公司将《"吉林敖东延吉药业科技园建设项目" 尚未投入的募集资金 50,974.83 万元及利息的用途变更为永久补充流动资金。具 体内容详见公司于 2020 年 ...

1、募集资金到位情况 经中国证券监督管理委员会《关于核准吉林敖东药业集团股份有限公司公 开发行可转换公司债券的批复》（证监许可[2018]184 号）核准，公司于 2018 年 3 月 13 日公开发行了面值总额 241,300 万元的可转换公司债券，扣除发行费 用 2,446.13 万元后，募集资金净额为 238,853.87 万元。截至 2018 年 3 月 19 日，上述募集资金已经到位。中准会计师事务所（特殊普通合伙）已对上述募 集资金到位情况出具了验资报告。公司依照规定对募集资金进行专户存储管理， 并与保荐机构、存放募集资金的商业银行签署了募集资金三方监管协议。 2、募集资金投资项目情况 证券代码:000623 证券简称:吉林敖东 公告编号:2024-063 吉林敖东药业集团股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林敖东药业集团股份有限公司（以下简称"公司"）于 2024 年 8 月 30 日召开第十一届董事会第十一次会议，第十一届监事会第十次会议分别审议通 过了《关于使用部分闲 ...

编制单位：吉林敖东药业集团股份有限公司 单位：元 吉林敖东药业集团股份有限公司 2024 年半年度非经营性资金占用及其他关联方资金往来情况汇总表 企业法定代表人：李秀林 主管会计工作负责人：张淑媛 会计机构负责人（会计主管人员）：李强 | 非经营性资金占用 | | | 占用方与上 | 上市公司核 | 2024 年期初 | 2024 年 1-6 月 | | 2024 年 1-6 | 2024 年 1-6 | | 2024 年 6 月 | 占用形成原因 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | | 市公司的关 | 算的会计科目 | 占用资金余额 | 占用累计发生金 | | 月占用资金 | 月偿还累计 | | 末占用资金 | | | | | | | | 联关系 | | | 额（不含利息） | | 的利息 | 发生金额 | | 余额 | | | | | 现大股东及其附属企业 | | - | - | - | - | | - | - ...

2024 年中期现金分红方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000623 证券简称：吉林敖东 公告编号：2024-061 吉林敖东药业集团股份有限公司 重要内容提示： 1、每股分配比例：每10股派发现金红利2.00元（含税）。 2、本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日 期将在权益分派实施公告中明确。 为深入响应《国务院关于加强监管防范风险推动资本市场高质量发展的若干 意见》（国发〔2024〕10 号）文件精神和相关要求，提高分红水平、增加分红频 次，提升投资者回报水平，进一步推动全体股东共享公司经营成果，提振投资者 对公司未来发展的信心，公司董事会结合公司整体发展战略和实际经营情况，拟 定 2024 年度中期利润分配预案为：以公司 2024 年度中期权益分派实施时股权登 记日的总股本为基数，向全体股东每 10 股派发现金红利 2.00 元（含税），送红 股 0 股（含税），不以公积金转增股本。 本次利润分配预案调整原则：若公司董事会及股东大会审议通过利润分配方 案日至实施权益分派股权登记日期间股本发生 ...